166 filings
Page 3 of 9
8-K
6jpa1j
10 Nov 22
T2 Biosystems Announces Third Quarter 2022 Financial Results
5:01pm
8-K
w33auf vn
7 Nov 22
Departure of Directors or Certain Officers
9:00am
8-K
oa9e1 kes9y41al
14 Oct 22
T2 Biosystems Highlights Multiple New Studies Demonstrating Improved Rapid Detection Across Several Patient Populations
9:00am
8-K
9al sdcc1
13 Oct 22
T2 Biosystems Announces Plan to Commercialize a Diagnostic Test for Early Lyme Disease
9:00am
8-K
7of57
12 Oct 22
Material Modifications to Rights of Security Holders
4:01pm
8-K
xma8u7s fisbfiu
12 Oct 22
T2 Biosystems Announces Preliminary Third Quarter 2022 Financial Results and Updates 2022 Financial Outlook
8:47am
8-K
ttis1qx
30 Sep 22
Entry into a Material Definitive Agreement
4:06pm
8-K
qn7cak22q mxmap56d
30 Sep 22
Entry into a Material Definitive Agreement
4:00pm
8-K
04hany0 ysrsaur70x
30 Aug 22
Other Events
9:00am
8-K
0f87csuhxi
17 Aug 22
T2 Biosystems Announces Second Quarter 2022 Financial Results
4:00pm
8-K
eue 1h2g5ch0lcyl6
9 Aug 22
T2 Biosystems to Explore Potential to Develop Rapid Molecular Diagnostic Test for Philip Trip Taylor, Gilmartin Group
8:31am
8-K
99hwas8z48e
25 Jul 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
10:00am
8-K
6l8kfkw3n7zqkm8
11 Jul 22
T2 Biosystems Receives FDA Breakthrough Device Designation for the T2Lyme Panel
8:30am
8-K
s3ylvsct7vb
6 Jul 22
T2 Biosystems Announces Preliminary Second Quarter 2022 Financial Results
8:43am
8-K
1oqhw hai7lgk2xkjz67
10 Jun 22
Other Events
8:50am
8-K
ath3ld4mv
24 May 22
Other Events
5:01pm
8-K
vlhz3lf
11 May 22
T2 Biosystems Announces First Quarter 2022 Financial Results
4:25pm
8-K
flnz828k6 oi
27 Apr 22
T2 Biosystems Announces Submission for FDA Breakthrough Device Designation for T2Biothreat Panel
8:30am
8-K
0v9i8v
12 Apr 22
Regulation FD Disclosure
4:01pm
8-K/A
k0utfb1ctvs8pgks
1 Apr 22
Entry into a Material Definitive Agreement
4:01pm